Pembrolizumab Injectable Product

DRUG2 trials

Sponsors

University of Turin, Italy, Baylor College of Medicine

Conditions

Ewing SarcomaHER-2 Protein OverexpressionNon Small Cell Lung Cancer PatientsOsteosarcomaRhabdomyosarcomaSarcomaSoft Tissue SarcomaSynovial Sarcoma

Phase 1

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

RecruitingNCT04995003

Baylor College of MedicineEwing Sarcoma, HER-2 Protein Overexpression, Osteosarcoma +5

Start: 2021-12-07End: 2043-06-30Target: 25Updated: 2026-01-22

Phase 2

Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

University of Turin, ItalyNon Small Cell Lung Cancer Patients

Start: 2018-01-01End: 2023-01-01Target: 126Updated: 2017-12-22